Progressive stock price target lowered to $346 at BofA on auto policy growth

Bank of America (BofA) has reduced its stock price target for Agios Pharma from $54 to $32 following disappointing results from a trial related to sickle cell disease (SCD). This downgrade reflects concerns about the company's future performance and market position.

Progressive stock has seen gains following Goldman Sachs' reaffirmation of a Buy rating, citing strong growth prospects for the company. This positive sentiment reflects investor confidence in Progressive's market performance and future potential.

William Blair has maintained an Outperform rating for Progressive's stock despite concerns regarding its growth. This decision reflects confidence in the company's potential to navigate current market challenges and sustain its performance.

Morgan Stanley has reaffirmed its stock rating for Progressive, despite the company's strong growth performance. This decision reflects the investment firm's cautious approach to the stock, indicating a belief that the current valuation may not fully reflect the potential for future growth.

Bank of America (BofA) has lowered its stock price target for Home Depot to $430, citing softness in the professional backlog. This adjustment reflects ongoing challenges the company faces in a sluggish housing market and rising inflation, which have negatively impacted consumer demand. The sentiment surrounding Home Depot's stock remains negative as it grapples with these economic pressures.

A recent Bank of America survey indicates that investors expect the euro to end 2026 within a range of $1.10 to $1.20, compared to its current value of $1.1587. This sentiment reflects a cautious outlook among investors regarding significant fluctuations in the euro-dollar exchange rate.

Bank of America (BofA) reports a shift in dollar positioning as investors reduce their short positions. This change indicates a growing confidence among investors regarding the dollar's stability and potential performance in the market. The report highlights the evolving dynamics in currency trading as market participants adjust their strategies.

BofA has raised its stock price target for Jazz Pharmaceuticals to $247, driven by the company's advancements in cancer drug development. This adjustment reflects positive market sentiment towards Jazz Pharmaceuticals, indicating confidence in its future performance and potential growth in the oncology sector.